ATE345120T1 - Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals - Google Patents

Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals

Info

Publication number
ATE345120T1
ATE345120T1 AT04757949T AT04757949T ATE345120T1 AT E345120 T1 ATE345120 T1 AT E345120T1 AT 04757949 T AT04757949 T AT 04757949T AT 04757949 T AT04757949 T AT 04757949T AT E345120 T1 ATE345120 T1 AT E345120T1
Authority
AT
Austria
Prior art keywords
calcium channel
compounds
antimuscarinics
urinary tract
subunit
Prior art date
Application number
AT04757949T
Other languages
English (en)
Inventor
Matthew Oliver Fraser
Karl Bruce Thor
Edward C Burgard
Lee R Brettman
Steven B Landau
Daniel J Ricca
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE345120T1 publication Critical patent/ATE345120T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Electrotherapy Devices (AREA)
AT04757949T 2003-03-21 2004-03-22 Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals ATE345120T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45683503P 2003-03-21 2003-03-21
US48614803P 2003-07-10 2003-07-10
US50957003P 2003-10-08 2003-10-08
US53487104P 2004-01-08 2004-01-08
US54825004P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ATE345120T1 true ATE345120T1 (de) 2006-12-15

Family

ID=33102559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04757949T ATE345120T1 (de) 2003-03-21 2004-03-22 Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals

Country Status (14)

Country Link
US (7) US20040198822A1 (de)
EP (2) EP1721607A1 (de)
JP (1) JP2006520799A (de)
KR (1) KR100742001B1 (de)
CN (1) CN1791399A (de)
AT (1) ATE345120T1 (de)
AU (1) AU2004224322A1 (de)
BR (1) BRPI0408608A (de)
CA (1) CA2519694A1 (de)
DE (1) DE602004003172T2 (de)
DK (1) DK1492519T3 (de)
ES (1) ES2275229T3 (de)
PL (2) PL1492519T3 (de)
WO (1) WO2004084879A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843303B1 (fr) * 2002-08-07 2006-01-21 R & D Pharma Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
AU2003303041B2 (en) * 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
EP1621193A3 (de) * 2002-12-20 2006-08-02 Dynogen Pharmaceuticals Inc. Behandlung nicht-schmerzhafter Blasenstörungen mit Kalziumkanalmodulatoren der alpha2-delta-Untereinheit
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US20070135377A1 (en) * 2004-12-10 2007-06-14 Roman Stephen B Thixotropic anti-viral formulation
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
WO2006082888A1 (ja) * 2005-02-03 2006-08-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
US20060217405A1 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EP1741444A1 (de) * 2005-07-05 2007-01-10 Jerini AG Antagonisten von Kinin zur Behandlung von Blasenfunktionsstoerungen
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1988886A1 (de) * 2006-02-13 2008-11-12 Intelgenx Corporation Pharmazeutische orale dosierform mit verzögerter freisetzung und herstellungsverfahren dafür
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
BRPI0812000A2 (pt) * 2007-05-30 2014-11-18 Microdose Therapeutx Inc Métodos e composições para administração de oxibutinina
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
WO2009151613A1 (en) * 2008-06-13 2009-12-17 Concert Pharmaceuticals, Inc. Oxybutynin derivatives
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
AU2009312474B2 (en) 2008-11-07 2014-12-04 Insuline Medical Ltd. Device and method for drug delivery
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
CN105381524A (zh) 2010-01-05 2016-03-09 微剂量治疗技术公司 吸入设备和方法
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20190049928A (ko) * 2012-01-04 2019-05-09 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
MY173582A (en) * 2012-01-04 2020-02-04 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
EP2612663A1 (de) * 2012-01-04 2013-07-10 Wellesley Pharmaceuticals, LLC Formulierung mit verlängerter Freisetzung zur Verringerung der Blasenentleerungshäufigkeit und Verwendungsverfahren dafür
EP2612662B1 (de) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Formulierung mit verzögerter Freisetzung zur Verringerung der Blasenentleerungshäufigkeit und Verwendungsverfahren dafür
CN107157991A (zh) * 2012-03-19 2017-09-15 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
AU2013318023A1 (en) * 2012-09-24 2015-04-02 Cormatrix Cardiovascular, Inc. Multi-needle injection apparatus and system for delivering pharmacological agents to biological tissue
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MA39272A (fr) * 2014-04-09 2015-10-14 Arven Ilac Sanayi Ve Ticaret As Formulations à libération prolongée de gabapentine
WO2016028238A1 (en) * 2014-08-22 2016-02-25 Koç Üniversitesi A ph responsive hybrid hydrogel and method of synthesis thereof
WO2016028237A1 (en) * 2014-08-22 2016-02-25 Koç Üniversitesi A novel ph responsive hydrogel and method of synthesis
DK3364993T3 (da) 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
WO2017197324A1 (en) * 2016-05-13 2017-11-16 The Board Of Trustees Of The Leland Stanford Junior University Adrenergic receptor modulating compounds and methods of using the same
US10238821B2 (en) 2016-10-11 2019-03-26 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
CN110770221B (zh) 2017-04-26 2023-09-08 卡维昂公司 用于改善记忆和认知以及用于治疗记忆和认知障碍的方法
BR112019024944A2 (pt) * 2017-05-26 2020-06-23 Novassay Sa Subunidade auxilária de canal de cálcio com porta de tensão alfa 2 delta e suas utilizações
TWI879741B (zh) * 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
KR20200056719A (ko) * 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
US20250381074A1 (en) * 2024-06-12 2025-12-18 Devin M. Yaeger Nasal passage insert and packaging assembly therefor
WO2026006315A1 (en) * 2024-06-24 2026-01-02 HUMANWELL PHARMACEUTICAL US, Inc. Bridged tricyclic gaba derivatives as calcium channel modulators, methods of making, and methods of using thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
AU7707994A (en) * 1993-09-30 1995-04-18 Tokyo Tanabe Company Limited Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient
US5698549A (en) * 1994-05-12 1997-12-16 Uva Patent Foundation Method of treating hyperactive voiding with calcium channel blockers
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6255526B1 (en) * 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
ZA989251B (en) * 1997-10-17 2000-04-10 Lilly Co Eli Potentiation of pharmaceuticals.
FR2771093B1 (fr) * 1997-11-19 2000-01-21 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
EP1082306A1 (de) * 1998-05-26 2001-03-14 Warner-Lambert Company Aminosäureverbindungen mit starrer konformation mit affinität für die alpha2delta untereinheit eines calciumkanals
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
HUP0200738A3 (en) * 1999-04-08 2003-03-28 Warner Lambert Co Method of the treatment of incontinence
DE60024995T2 (de) * 1999-07-02 2006-06-22 Warner-Lambert Co. Llc Synergistische kombination: gabapentin und pregabalin
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
IL153398A0 (en) * 2000-06-16 2003-07-06 Teva Pharma Stable gabapentin containing more than 20 ppm of chlorine ion
CN1447684A (zh) * 2000-06-16 2003-10-08 特瓦制药工业有限公司 具有在可控制范围内的pH值的稳定的加巴喷丁
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
WO2002043763A2 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
PL372210A1 (en) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法

Also Published As

Publication number Publication date
PL1492519T3 (pl) 2007-04-30
US20060247311A1 (en) 2006-11-02
JP2006520799A (ja) 2006-09-14
US20080085916A1 (en) 2008-04-10
US20070060652A1 (en) 2007-03-15
US20080275080A1 (en) 2008-11-06
AU2004224322A2 (en) 2004-10-07
DE602004003172T2 (de) 2007-09-27
US20050239890A1 (en) 2005-10-27
KR20050111784A (ko) 2005-11-28
BRPI0408608A (pt) 2006-03-07
EP1492519A1 (de) 2005-01-05
EP1721607A1 (de) 2006-11-15
DK1492519T3 (da) 2007-03-05
US20040198822A1 (en) 2004-10-07
ES2275229T3 (es) 2007-06-01
PL378583A1 (pl) 2006-05-02
AU2004224322A1 (en) 2004-10-07
DE602004003172D1 (de) 2006-12-28
WO2004084879A1 (en) 2004-10-07
CN1791399A (zh) 2006-06-21
CA2519694A1 (en) 2004-10-07
EP1492519B1 (de) 2006-11-15
US20110294881A1 (en) 2011-12-01
KR100742001B1 (ko) 2007-07-23

Similar Documents

Publication Publication Date Title
ATE345120T1 (de) Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
EA200401127A1 (ru) АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2δ-БЕЛКУ
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE522229T1 (de) Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60315258D1 (de) Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten
DE602004017888D1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
Solimeno et al. Knee arthropathy: when things go wrong
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
IS8162A (is) Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni
BRPI0414798A (pt) métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
NO20045089L (no) Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser
ATE430578T1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE60131100D1 (de) Verfahren zur behandlung bestimmter augenkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1492519

Country of ref document: EP

REN Ceased due to non-payment of the annual fee